AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph beginning at page 5, line 6, as follows:

Preferably, the adhesive, solid therapeutic composition according to the invention comprises 0.1 to 15 by weight percent of the active herbal ingredient(s), 50 to 65 by weight percent lactose, 10 to 20 weight percent of an adhesive polymer of acrylic acid which is preferably ~~carbopol 974P®~~CARBOPOL 974P (available from the Lubrizol Corporation), and 10 to 20 weight percent of polyvinylpyrrrolidone, which is preferably povidone K-90® or povidone K-29-32®.

Please amend the paragraph beginning at page 5, line 19, as follows:

According to another embodiment of the invention, the composition comprises an adhesive polymer of cellulose derivative, which is preferably hydroxypropyl cellulose (~~Klucel~~ KLUCEL XHF® (available from Hercules Inc.).

Please amend the paragraph beginning at page 9, line 3, as follows:

The dry, milled granulate obtained is mixed with active extracts of one or more of the plants *Sambucus nigra*, *Centella asiatica* and *Echinacea purpurea*, the adhesive polymer of polyacrylic acid, which is preferably ~~carbomer 974P~~ CARBOPOL 974P and the additional amount of povidone K-90, and, optionally, with an adhesive polymer of a cellulose derivative, which is preferably hydroxypropyl cellulose (~~Klucel~~ KLUCEL XHF®) and, if desired, with flow agents, such as colloidal silicon dioxide and flavoring

agents. The mixing operation is preferably carried out in a V-shaped blender for several minutes. A lubricant, which is most preferably magnesium stearate, is introduced at this stage into the resultant mixture, and the blending is continued for additional one to three minutes. The mixture may be compressed using a rotary tableting machine to produce the core tablets.